Cookies enable us to provide a personalized experience and are necessary. By using this website, you agree to the use of cookies.

OK Information

Information Cookies

This website uses cookies to store information about user preferences, on which pages visits, to customize the content according to the user's browser or similar. Some of our servers of advertising (Google Adsense and others) may use cookies and web beacons on our website. These external advertising servers automatically receive the IP address of our visitors, which is necessary for its own operation. Likewise, you can use other technologies, such as cookies, JavaScript, or web beacons, to study the effectiveness of their ads or customize its content. This website has no control over such technologies used by external advertising servers. You can consult their respective privacy policies for more information.

If you want to disable the use of cookies, you can do so through the options of your browser (more info in their respective help).

Abnova
World's Largest Antibody and Recombinant Protein Manufacturer Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Founded in 2002 at the height of the genomic era, Abnova‘s vision is the production and application of antibodies derived from the “one gene one antibody...
World's Largest Antibody and Recombinant Protein Manufacturer Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Founded in 2002 at the height of the genomic era, Abnova‘s vision is the production and application of antibodies derived from the “one gene one antibody” translation of entire human genome. The company’s first goal is to vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. As such, Abnova has produced 19,000+ recombinant proteins, 12,000+ MaxPab antibodies, 16,000+ monoclonal antibodies, and 20,000+ polyclonal antibodies targeting the human genome. Since 2009, Abnova has diversified into the systems arena focusing on antibody pairs, ELISA kits, instrumentations for biomarker screening and protein quantification in the short-term (1-3 years), diagnostic development concentrating on infection, cancer, endocrine and metabolism in the mid-term (3-5 years), and drug development specializing on CD molecule and GPCR monoclonal antibody in the long-term (5-7years).
More

Abnova There are no products in this category.